NCT04605718View on ClinicalTrials.gov

A Study To Investigate The Safety, Tolerability And Pharmacokinetics (PK) Of RO7223280 Following Intravenous Administration In Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

March 9, 2023

Study Completion Date

March 9, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

RO7223280

For Part 1 (SAD) and Part 2 (MAD), RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg, as per the dosing schedules described above. These are putative doses and the maximum daily dose that must not be exceeded is 5000mg. For Part 3 (Elderly), RO7223280 will be administer as one single IV dose of 300 mg.

Trial Locations (1)

53704

Covance Clinical Research Unit, Inc, Madison

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT04605718 - A Study To Investigate The Safety, Tolerability And Pharmacokinetics (PK) Of RO7223280 Following Intravenous Administration In Healthy Participants | Biotech Hunter | Biotech Hunter